Zafiris Kartasis

1.2k total citations
16 papers, 676 citations indexed

About

Zafiris Kartasis is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Zafiris Kartasis has authored 16 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Zafiris Kartasis's work include Multiple Myeloma Research and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Peptidase Inhibition and Analysis (4 papers). Zafiris Kartasis is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Peptidase Inhibition and Analysis (4 papers). Zafiris Kartasis collaborates with scholars based in Greece, Italy and Netherlands. Zafiris Kartasis's co-authors include Meletios Α. Dimopoulos, Efstathios Kastritis, Dimitra Gika, Eurydiki Michalis, Argiris Symeonidis, Evangelos Terpos, Anastasia Pouli, Eirini Katodritou, Konstantinos Zervas and Agapi Parcharidou and has published in prestigious journals such as Blood, Annals of Oncology and Leukemia.

In The Last Decade

Zafiris Kartasis

16 papers receiving 663 citations

Peers

Zafiris Kartasis
Eurydiki Michalis Greece
Evridiki Michali Greece
Grigoriy Rekhtman Ukraine
Amalia Vassou Greece
Giulia Benevolo Italy
Diane Warren United States
David H. Vesole United States
Lucia Pantani Italy
Maria Gavino United States
Anita Zahlten‐Kumeli United States
Eurydiki Michalis Greece
Zafiris Kartasis
Citations per year, relative to Zafiris Kartasis Zafiris Kartasis (= 1×) peers Eurydiki Michalis

Countries citing papers authored by Zafiris Kartasis

Since Specialization
Citations

This map shows the geographic impact of Zafiris Kartasis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zafiris Kartasis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zafiris Kartasis more than expected).

Fields of papers citing papers by Zafiris Kartasis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zafiris Kartasis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zafiris Kartasis. The network helps show where Zafiris Kartasis may publish in the future.

Co-authorship network of co-authors of Zafiris Kartasis

This figure shows the co-authorship network connecting the top 25 collaborators of Zafiris Kartasis. A scholar is included among the top collaborators of Zafiris Kartasis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zafiris Kartasis. Zafiris Kartasis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Gavriatopoulou, Maria, Ramón García‐Sánz, Efstathios Kastritis, et al.. (2016). BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 129(4). 456–459. 53 indexed citations
2.
3.
Dimopoulos, Meletios Α., Evangelos Terpos, Maria Gavriatopoulou, et al.. (2014). Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood. 124(21). 4738–4738. 3 indexed citations
4.
Dimopoulos, Meletios Α., Sosana Delimpasi, Eirini Katodritou, et al.. (2013). Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of Oncology. 25(1). 195–200. 109 indexed citations
5.
Dimopoulos, Meletios Α., Ramón García‐Sánz, Maria Gavriatopoulou, et al.. (2013). Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 122(19). 3276–3282. 135 indexed citations
6.
Dimopoulos, Meletios Α., Sosana Delimpasi, Eirini Katodritou, et al.. (2012). Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. Blood. 120(21). 948–948. 1 indexed citations
7.
Dimopoulos, Meletios Α., Efstathios Kastritis, Sossana Delimpasi, et al.. (2012). Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal Of Haematology. 89(1). 10–15. 27 indexed citations
8.
Dimopoulos, Meletios Α., Efstathios Kastritis, Eurydiki Michalis, et al.. (2011). The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Annals of Oncology. 23(3). 722–729. 19 indexed citations
9.
Kastritis, Efstathios, Eirini Katodritou, Anastasia Pouli, et al.. (2011). Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood. 118(21). 5083–5083. 5 indexed citations
10.
Terpos, Evangelos, Eirini Katodritou, Μαρία Ρούσσου, et al.. (2010). High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. European Journal Of Haematology. 85(2). 114–119. 102 indexed citations
11.
Dimopoulos, Meletios Α., Ramón García‐Sánz, Maria Gavriatopoulou, et al.. (2010). Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood. 116(21). 1941–1941. 2 indexed citations
12.
13.
Galanopoulos, Athanasios, Agapi Parcharidou, Krinio Giannikou, et al.. (2009). Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 95(3). 406–414. 36 indexed citations
14.
Tsatalas, Costas, et al.. (2004). Amifostine Stimulates the Formation of Hematopoietic Bone Marrow Progenitors from B-Cell Chronic Lymphocytic Leukemia. Acta Haematologica. 112(3). 136–140. 2 indexed citations
15.
Mimidis, Konstantinos, et al.. (2004). Assessment of platelet adhesiveness and aggregation in mild acute pancreatitis using the PFA-100 system.. PubMed. 5(3). 132–7. 20 indexed citations
16.
Tsatalas, Costas, Ιoannis Kotsianidis, Anastasios J. Karayiannakis, et al.. (2003). Splenectomy for Massive Splenic Infarction Unmasks Paroxysmal Nocturnal Hemoglobinuria. Acta Haematologica. 110(4). 193–196. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eurydiki Michalis Breakdown of academic impact, for papers by Evridiki Michali Breakdown of academic impact, for papers by Grigoriy Rekhtman Breakdown of academic impact, for papers by Amalia Vassou Breakdown of academic impact, for papers by Giulia Benevolo Breakdown of academic impact, for papers by Diane Warren Breakdown of academic impact, for papers by David H. Vesole Breakdown of academic impact, for papers by Lucia Pantani Breakdown of academic impact, for papers by Maria Gavino Breakdown of academic impact, for papers by Anita Zahlten‐Kumeli
Rankless by CCL
2026